Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some sildenafil-specific safety and contraindication claims align with the label (notably nitrates and common adverse reactions). However, several claims are not supported by the provided label text (e.g., India-specific market composition, onset/duration comparisons, and an absolute “should not self-medicate” framing for cardiovascular/low blood pressure that the label presents as physician assessment/caution rather than a direct self-medication prohibition).
Category Scores
Accurate Statements
Viagra is sildenafil.
11 DESCRIPTION (VIAGRA (sildenafil citrate)).
ED medicines that include sildenafil can be risky with nitrates (often used for chest pain).
4 CONTRAINDICATIONS; 4.1 Nitrates (VIAGRA potentiates hypotensive effects; contraindicated with nitric oxide donors such as organic nitrates/nitrites).
Side effects of sildenafil (or similar ED drugs) can include headache.
6 ADVERSE REACTIONS (most common adverse reactions include headache).
Side effects of sildenafil (or similar ED drugs) can include flushing.
6 ADVERSE REACTIONS (most common adverse reactions include flushing).
Side effects of sildenafil (or similar ED drugs) can include indigestion.
6 ADVERSE REACTIONS (most common adverse reactions include dyspepsia).
Side effects of sildenafil (or similar ED drugs) can include nasal congestion.
6 ADVERSE REACTIONS (most common adverse reactions include nasal congestion).
Side effects of sildenafil (or similar ED drugs) can include dizziness.
6 ADVERSE REACTIONS (most common adverse reactions include dizziness).
Side effects of sildenafil (or similar ED drugs) can include vision changes.
6 ADVERSE REACTIONS (most common adverse reactions include abnormal vision).
Unsupported Statements
Many ED products sold in India use sildenafil as the active ingredient.
Not supported by the provided label sections (label does not address India market composition).
Some ED medicines sold in India use tadalafil as the active ingredient.
Not supported by the provided label sections (label does not discuss tadalafil or regional market composition).
ED products sold in India can differ by active ingredient (commonly sildenafil vs. tadalafil).
Not supported by the provided label sections.
ED products sold in India can differ by strength (mg).
Not supported by the provided label sections for comparative statements about other products/markets.
Sildenafil often has a shorter onset/duration window than tadalafil.
Not supported by the provided label sections (no tadalafil comparison or onset/duration comparison included).
ED products sold in India can differ by formulation (tablets vs. other forms).
Not supported by the provided label sections.
ED products sold in India can differ in whether they are the same drug or a different ED class.
Not supported by the provided label sections.
The fastest way to compare ED products sold in India is to check the active ingredient on the label.
Not supported by the provided label sections (label does not provide consumer guidance for comparing non-VIAGRA products).
In practice, many ED medicines in India are treated as prescription drugs.
Not supported by the provided label sections.
ED medicines that include sildenafil can be risky with some blood-pressure medicines.
Partially supported only for specific labeled class interactions (alpha-blockers/anti-hypertensives). The broad wording 'some blood-pressure medicines' is not fully supported as stated.
Contradictions
Low
AI Statement
If you have heart disease, you should not self-medicate with sildenafil-containing ED medicines.
Label Reference
5.1 Cardiovascular
Low
AI Statement
If you have low blood pressure, you should not self-medicate with sildenafil-containing ED medicines.
Label Reference
5.1 Cardiovascular
Important Omissions
For the 'blood-pressure medicines' and 'self-medication' claims, the label-supported nuance that use requires physician evaluation/caution (e.g., stable on alpha-blockers, lowest dose, resting hypotension listed for caution) is not provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Nitrate contraindication and common adverse reactions are accurately reflected. However, several unsourced broad claims about other-market products and an overly absolute 'do not self-medicate' framing for cardiovascular/low blood pressure are not precisely supported by the provided label wording, which may lead to misinterpretation of labeled cautions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label (especially India-specific market composition and sildenafil vs tadalafil onset/duration/formulation comparisons). Additionally, 'should not self-medicate' statements are stronger than the label's 'physician assessment/caution' language.
Suggested Improvement
Restrict claims to label-supported facts (sildenafil identity, contraindication with nitrates/NO donors, and listed common adverse reactions). Replace absolute self-medication prohibitions with the label's cautions/assessment language for cardiovascular disease and resting hypotension, and avoid market/comparative statements not present in the provided label text.